The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
MicroRNA-mediated drug resistance in breast cancer
Open accessAbstract
Chemoresistance is one of the major hurdles to overcome for the successful treatment of breast cancer. At present, there are several mechanisms proposed to explain drug resistance to chemotherapeutic agents, including decreased intracellular drug concentrations, mediated by drug transporters and metabolic enzymes; impaired cellular responses that affect cell cycle arrest, apoptosis, and DNA repair; the induction of signaling pathways that promote the progression of cancer cell populations; perturbations in DNA methylation and histone modifications; and alterations in the availability of drug targets. Both genetic and epigenetic theories have been put forward to explain the mechanisms of drug resistance. Recently, a small non-coding class of RNAs, known as microRNAs, has been identified as master regulators of key genes implicated in mechanisms of chemoresistance. This article reviews the role of microRNAs in regulating chemoresistance and highlights potential therapeutic targets for reversing miRNA-mediated drug resistance. In the future, microRNA-based treatments, in combination with traditional chemotherapy, may be a new strategy for the clinical management of drug-resistant breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 4×
“Through sequence-specific interactions between the mature miRNA and mRNA, the ribonucleoprotein complex is positioned on either the 3′- or 5′-untranslated region (UTR) of their targets, resulting in mRNA cleavage if complementarity is perfect or, in the case of imperfect base pairing, translational repression (Bartel…”
BackgroundInfluentialCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221 · cited 5×
“Additionally, activation of BRCA1 is disrupted by deficiencies in the DNA damage sensor, ATM (Wang et al. 2000).”
BackgroundInfluentialA Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer
Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C. B., & Liu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013735 · Cited by 398
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173483 · Cited by 255
Epigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
Baker, E. K., Johnstone, R. W., Zalcberg, J. R., & El-Osta, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208955 · Cited by 196
Cited by
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer
Svoronos, A. A., Engelman, D. M., & Slack, F. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0359 · Cited by 791
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
3D Bioprinting of Breast Cancer Models for Drug Resistance Study
Wang, Y., Shi, W., Kuss, M., Mirza, S., Qi, D., Krasnoslobodtsev, A., Zeng, J., Band, H., Band, V., & Duan, B. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01277 · Cited by 157
Metadata
- Authors
- Kutanzi, K. R., Yurchenko, O. V., Beland, F. A., Checkhun, V. F., & Pogribny, I. P.
- Venue
- Clinical Epigenetics
- Published
- 2011-06-27
- Volume
- 2
- Issue
- 2
- Pages
- 171-185
- ISSN
- 1868-7075 (ISSN-L)
- 1868-7083
- OpenAlex
- W1990965835
- Cited by
- 170
- References
- 10
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MicroRNA-mediated drug resistance in breast cancer. https://app.cochat.ai/papers/10.1007/s13148-011-0040-8
- The paper
- Kutanzi, K. R., Yurchenko, O. V., Beland, F. A., Checkhun, V. F., & Pogribny, I. P. (2011). MicroRNA-mediated drug resistance in breast cancer. Clinical Epigenetics. https://doi.org/10.1007/s13148-011-0040-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.